EuBiologics유바이오로직스
206650 · KOSDAQ · ₩206650 · 유바이오로직스
₩7,500▲ ₩40 (0.54%)End-of-day · Oct 27, 2026 · End-of-day prices.
Filings
- Major sales or supply contract단일판매ㆍ공급계약체결(자율공시)Oct 26, 2026Open on DART
Predicted impact: Low
Single supply contract disclosed with no value given; size relative to revenue unknown.
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (대상포진 예방 백신 EuHZV(유에이치지브이)주의 제1상 국내 임상시험 결과)Oct 21, 2026Open on DART
Predicted impact: Low
Official filing of the same Phase 1 results repeats the announcement already made in the headline item.
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (대상포진 예방 백신 EuHZV(유에이치지브이)주의 제2상 임상시험계획승인 신청(IND))Oct 21, 2026Open on DART
Predicted impact: Low
IND filing for Phase 2 trial repeats the same pipeline news already covered by the Phase 1 results announcement.
- Change of Head Office Location본점소재지변경Oct 6, 2026Open on DART
- Amended: Acquisition of shares in another company[기재정정]타법인주식및출자증권취득결정Aug 26, 2026Open on DART
- Trust Contract Termination Result Report신탁계약해지결과보고서Aug 24, 2026Open on DART
- Share cancellation decision주식소각결정Aug 21, 2026Open on DART
- Material Matters Report (Decision on Termination of Trust Agreement for Own Share Acquisition)주요사항보고서(자기주식취득신탁계약해지결정)Aug 21, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (알츠하이머병 대응 백신 PADIVAX의 제1상 임상시험계획승인 신청(IND))Aug 18, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 13, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (호흡기세포융합바이러스 (Respiratory Syncytial Virus,RSV) 예방 백신 (EuRSV, 유알에스브이)의 제1상 국내 임상시험 결과)Jul 27, 2026Open on DART
- Amended: Major sales or supply contract[기재정정]단일판매ㆍ공급계약체결(자율공시)Jul 16, 2026Open on DART
- Major sales or supply contract단일판매ㆍ공급계약체결(자율공시)Jul 14, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 6, 2026Open on DART
- Status Report on Acquisition Under Trust Agreement신탁계약에의한취득상황보고서Jul 2, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Jun 30, 2026Open on DART
- Major sales or supply contract단일판매ㆍ공급계약체결Jun 16, 2026Open on DART
- Major sales or supply contract단일판매ㆍ공급계약체결(자율공시)Jun 5, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최May 29, 2026Open on DART
- Major sales or supply contract단일판매ㆍ공급계약체결(자율공시)May 19, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 14, 2026Open on DART
- Change of Department Affiliation소속부변경Apr 30, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 30, 2026Open on DART
- Amended: Acquisition of shares in another company[기재정정]타법인주식및출자증권취득결정Apr 22, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Apr 7, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 7, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 3, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Mar 27, 2026Open on DART
- Acquisition of shares in another company타법인주식및출자증권취득결정Mar 26, 2026Open on DART
- Other management matters기타경영사항(자율공시) (주식기준성과보상제도(RSU)관련 자기주식 교부 예고)Mar 26, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 26, 2026Open on DART
- Buyback trust contract signed주요사항보고서(자기주식취득신탁계약체결결정)Mar 26, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 26, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Mar 18, 2026Open on DART
- Audit report submitted감사보고서제출Mar 17, 2026Open on DART
- Amended: Notice of shareholders' meeting[기재정정]주주총회소집공고Mar 17, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 17, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 11, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 11, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 5, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 4, 2026Open on DART
- New Facility Investment, etc.신규시설투자등Feb 2, 2026Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 2, 2026Open on DART
- Major sales or supply contract단일판매ㆍ공급계약체결(자율공시)Jan 23, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 2, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (SARS-CoV-2 변이주 대응 mRNA백신 mCOV의 제1상 임상시험계획 승인)Dec 23, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 12, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Dec 3, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: EuBiologics / 유바이오로직스 / 206650 / KRX:206650
Source: KRX statistical information